share_log

Benuvia To Go Public Via SPAC Deal With Pono Capital, Deal Valued At $440M

Benzinga Real-time News ·  Mar 18, 2022 06:07
  • Benuvia,a leading drug developer focused on pharmaceutical cannabinoidshas entered into a definitive business combination agreement withPonoCapital Corp(NASDAQ:PONO)
  • The transaction implies a combined company pro forma enterprise value of$440 million
  • BenuviaownsSYNDROS®,the FDA approveddronabinol(THC) oral solution, CII, which is approved for chemotherapy-induced nausea and vomitingin cancer patientsand loss of appetite in AIDS patients who have lost weight,andis pursuingthree additional INDs basedonthe same formulation as SYNDROS®
  • Benuviamanufactures active pharmaceutical ingredients in its83,000 square foot manufacturing facilitythat ispermitted by...
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment